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Dry eye is a common problem worldwide, and it has been reported that 70% of dry eye has an evaporative component \[[@CR1]\]. The major cause of evaporative dry eye is meibomian gland dysfunction (MGD). In MGD, the occlusion of the terminal ducts leads to a cascade of changes including retention of meibomian lipids, abnormal tear lipid layer, signs of evaporative dry eye, as well as atrophy and loss of meibomian glands. A recent international workshop by international experts mentioned that there is an unmet medical need in MGD, research in MGD is a priority, and one essential tool for translational research is an appropriate animal model. With increased clinical interest in MGD as it relates to tear stability and tear lipid chemistry, development of an animal model for MGD is paramount. New therapeutic medical devices for MGD are now available. There is increased interest in the development of lipid-containing eyedrops. It is advantageous to evaluate efficacy and safety of these new treatments in pre-clinical studies \[[@CR2]\]. Currently available animal models resemble only one or more of these pathophysiological aspects, but are dissimilar to human MGD in other ways, either in the chronicity of the disease or the requirement for glandular occlusion to be the initiating event in the disease. It is important to avoid excessive pain when inducing the MGD features in animals.

An ideal animal model for MGD should include anatomical features of human disease, such as obstruction of the glands, keratinisation of the ducts, and dilatation of the ductules. As in human disease, the observable characteristics should diffusely affect the entire lids in a chronic or progressive manner, with fibrosis or edema of the eyelid margin. Even though the lipids of murine meibum are quite different from humans \[[@CR3]\], there is likely biochemical abnormality in the animal tear or meibum that can be measured after induction of disease, such as changes in saturation of wax esters, decreases in O-acyl ω-hydroxyl fatty acids (OAHFAs), or increases in lysophospholipids. Ideally, there should be a high success rate for induction of the MGD, and animals involved should have normal lifespan and have little to no involvement of other systemic organs.

Here we review the features of the reported animal models (mouse and rat) that exhibit abnormalities in meibomian glands (Table [1](#Tab1){ref-type="table"}). Animal models that report primarily blepharits \[[@CR4]\] or reflect an ocular surface dessication model with secondary MGD \[[@CR5]\] are not included in the discussion. There are some pros and cons for each of the models reported. Several animal models are suitable for evaluation of developmental abnormalities of meibomian glands, for example, a mutation in the EDARadd gene resulted in rats with abnormal meibomian, sweat, mammary, and other exocrine glands \[[@CR6]\]. Such models may or may not reflect acquired disease that obstruct the meibomian glands. As MGD is more common in older people, a model that used superoxide dismutase deletion in mice reflects human disease in that these mice also show age-related MGD features. Furthermore, this model also presents with evaporative dry eye features that improved after treatment \[[@CR7]\]. Superoxide dismutase is an important enzyme that sequesters free radicals, and in the absence of this enzyme, free radicals tend to increase, which is a phenomenon observed in aging cells and tissues. A mouse model that used cautery was successful in the induction of MGD after 4 and 8 weeks due to induction of post-cautery fibrosis, suggesting that glandular changes were secondary to obstruction \[[@CR8]\]. Another model in rabbits using cautery of meibomian glands has also been reported \[[@CR9]\]. Two other interesting novel models of MGD include one that is HR-1 mice fed with a lipid limiting diet \[[@CR10]\], the other an aggravated allergic model that involved infiltration of eyelid neutrophils and IL17-mediated inflammation \[[@CR11]\].Table 1Animal models showing abnormal meibomian glandsModelDescriptionAnimalMGD featuresOther defects^a^Pikus et al. \[[@CR13]\]Modulation of bone morphogenic protein (BMP)K14-Noggin transgenic mouseAbnormal meibomian glandsAbnormal sweat glands, ectopic cilia, distal limb agenesis, hyperpigmentation of claws, interdigital webbing, reduced foot padsCascallana et al. \[[@CR14]\]Overexpression of glucocorticoid receptorK5-GR miceLack meibomian glandsUnderdeveloped sweat glands, preputial glands; abnormal hair follicles, teeth, and palateChang et al. \[[@CR15]\]Elevation of EDAR signallingTransgenic miceEnlarged meibomian glandsExcessively branched mammary and salivary glandsKuramoto et al. \[[@CR6]\]EDARadd gene missense mutationSparse-and-wavy (swh) ratDefective meibomian glandsDefects in the sweat, mammary, preputial, and tongue glandsCui et al. \[[@CR16]\] and Wang et al. \[[@CR17]\]Mutation of X-linked anhidrotic ectodermal dysplasia (EDA) gene"Tabby" miceLack meibomian glands, reduced tear break up times, blepharitisCorneal neovascularization, ulceration, keratinization, reduced corneal epithelial microvilli, conjunctivitis^b^Lin et al. \[[@CR18]\]Mice lacking fatty acid transport protein (FATP)4Tg (IVL-Fatp4) transgenicmiceUnder developed meibomian glands with thickened ductsAbnormal sebaceous glands, thick skin with defective barrierMcMahon et al. \[[@CR19]\]Mutation in ELOVL4 (enzyme for synthesis of extremely long chain fatty acid)heterozygous Stgd3 mice, mixed 129SvEv and C57BL6Protruding meibomian gland orifice, intragland anatomical changes, tooth paste like meibum, intense staining for ELOVL4 in glandsInability to open eyes fully, increased blink ratesIkeda et al. \[[@CR7]\]Superoxide dismutase (SOD)-1 knock outMice with F1 backgroundAge related meibomian gland abnormalities (reduced glandular oil-red O staining)Corneal fluorescein and lissamine staining, reduced tear secretion (phenol red thread readings)Gilbard 1989 \[[@CR9]\]Cautery of meibomian gland orificeRabbitsIncreased tear film osmolarity, decrease in conjunctival goblet cells and corneal epithelial glycogen levelsNilNichols et al. \[[@CR8]\]Cautery of meibomian gland orificeMiceMeibomian gland ductal engorgement and cyst formation, gland dropout, cheesy glandular inclusionsNilMiyake et al. \[[@CR10]\]Lipid limiting dietHR-1/HR-AD hairless micePlugged meibomian gland orifice\
Hyperkeratinisation of meibomian duct epithelium; loss of acini and gland atrophyAtopic dermatitis \[[@CR20]\]Reyes et al. \[[@CR11]\]Immunisation with ovalbumin and pertussis, then topical challengeC57B6 micePlugged meibomian gland orifice, presence of neutrophils around meibomian glandsNil reported^a^Genetic models refer to homozygous mice^b^Not in mice expressing the EDA-A1 isoform transgene

There is much unknown in this exciting research area. Some of the more recent studies evaluated here have only been reported in conference proceedings, and there is no doubt that the search is ongoing for a better and more convenient animal model of MGD. Newer imaging modalities and robust biochemical techniques will be employed in the evaluation of these future animal models. Novel image analysis algorithms would be useful for in vivo confocal microscopy, which is a non-destructive process. In tissue sections non-linear optical imaging and volumetric analysis of meibomian glands is a promising technique \[[@CR12]\]. In cases where inflammation is to be evaluated, observation of leukocytes in two-photon live microscopy may be useful. These novel techniques will likely further our understanding of newer therapies of MGD such as probing and intense pulse light, as to date there are no suitable models to assess the effects of these therapies at the microscopic level.
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